tetano
Editor, Senior Moderator
Vaccine. 2011 Nov 7. [Epub ahead of print]
Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.
Smith JH, Papania M, Knaus D, Brooks P, Haas DL, Mair R, Barry J, Tompkins SM, Tripp RA.
Source
College of Veterinary Medicine, Department of Infectious Diseases, University of Georgia, Athens, GA 30602, United States.
Abstract
Live-attenuated influenza vaccine (LAIV) is delivered to vaccine recipients using a nasal spray syringe. LAIV delivered by this method is immunogenic at current doses; however, improvements in nasal delivery might allow for significant dose reduction. We investigated LAIV vaccination in ferrets using a high efficiency nebulizer designed for nasal delivery. LAIV nasal aerosol elicited high levels of serum neutralizing antibodies and protected ferrets from homologous virus challenge at conventional (10(7)TCID(50)) and significantly reduced (10(3)TCID(50)) doses. Aerosol LAIV also provided a significant level of subtype-specific cross-protection. These results demonstrate the dose-sparing potential of nebulizer-based nasal aerosol LAIV delivery.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
22075083
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22075083
Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.
Smith JH, Papania M, Knaus D, Brooks P, Haas DL, Mair R, Barry J, Tompkins SM, Tripp RA.
Source
College of Veterinary Medicine, Department of Infectious Diseases, University of Georgia, Athens, GA 30602, United States.
Abstract
Live-attenuated influenza vaccine (LAIV) is delivered to vaccine recipients using a nasal spray syringe. LAIV delivered by this method is immunogenic at current doses; however, improvements in nasal delivery might allow for significant dose reduction. We investigated LAIV vaccination in ferrets using a high efficiency nebulizer designed for nasal delivery. LAIV nasal aerosol elicited high levels of serum neutralizing antibodies and protected ferrets from homologous virus challenge at conventional (10(7)TCID(50)) and significantly reduced (10(3)TCID(50)) doses. Aerosol LAIV also provided a significant level of subtype-specific cross-protection. These results demonstrate the dose-sparing potential of nebulizer-based nasal aerosol LAIV delivery.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
22075083
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22075083